+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Anti Inflammatory Drugs Market - Growth, Trends, and Forecast (2020 - 2025)

  • PDF Icon


  • 112 Pages
  • August 2020
  • Region: Global
  • Mordor Intelligence
  • ID: 4896038
UP TO OFF until Dec 31st 2023
Anti-inflammatory drugs are the drugs that are used to treat conditions like Asthma, Arthritis, Chronic obstructive pulmonary disease (COPD) and other diseases. Increasing prevalence of these diseases is the major factor propelling the market upwards. Although documented incidences of side effects and patent expiration of Blockbuster drugs are restraining the market growth, new research advancements in Anti Inflammatory Biologics, Immune Selective Anti-Inflammatory Derivatives (ImSAIDs), etc. are helping to make this class of drugs as side effect free as possible, maintaining the efficacy and potency of the drug.

Moreover, increasing awareness of anti-inflammatory therapeutics and attractive government initiatives are expected to drive the overall market.

Key Market Trends

Anti Inflammatory Drugs for Arthritis Treatment is Found Dominating the Market

Arthritis is the inflammation in the joints. There are different types of arthritis, osteoarthritis and rheumatoid arthritis being most common among them. Arthritis is found to be more prevalent in the geriatric population, but there have been some documented cases of arthritis in children as well. Other common forms of arthritis include psoriatic arthritis, fibromyalgia and gout.

Osteoarthritis is caused due to the breakdown of protective cartilage, causing pain and movement of joints difficult. Non-steroidal Anti-Inflammatory drugs (NSAIDs) like diclofenac, ibuprofen and naproxen have been proven to be very effective in suppressing the pain from Osteoarthritis but may cause side effects like stomach upset, cardiovascular problems, bleeding problems, and liver and kidney damage. NSAID gels have also been proven to alleviate the pain and have lesser side effects. Doctors have been turning towards prescribing newest form of Anti-Inflammation drugs called Biologics.

The risk of arthritis has only increased in recent times due to an increase in the sedentary lifestyle, obesity, and unhealthy food habits. Hence, the drug market for its treatment will only see growth in recent future.

North America is Expected to Dominate the Anti-Inflammatory Drugs Market

North America is the largest market in the Anti-Inflammatory Drugs Market due to the factors such as established healthcare sector with a large number of renowned players, high investment & demand for more effective and safer drugs, etc. Moreover, the high income per capita, rise in patient visits to physicians, research advancements due to high funding are some of the factors that are driving the growth of the North American market.

However, Asia Pacific is expected to emerge as the fastest market, driven by a vast patient pool, increasing disposable incomes, growth in healthcare spending, and rising awareness about health.

Competitive Landscape

Majority of the Anti-Inflammatory drugs are being manufactured by the global key players. Market leaders with more funds for research and better distribution system have established their position in the market.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Incidences of Autoimmnue and Respiratory Conditions
4.2.2 Growing Research for Safer New Anti-Inflammatory Drugs
4.3 Market Restraints
4.3.1 Side Effects of Anti-Inflammtory Drugs
4.3.2 Patent Expiration
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1 By Treatment
5.1.1 Arthritis
5.1.2 Chronic obstructive pulmonary disease (COPD)
5.1.3 Multiple Sclerosis
5.1.4 Inflammatory bowel disease (IBD)
5.1.5 Asthma
5.1.6 Tendonitis
5.1.7 Other Treatments
5.2 By Drug Class
5.2.1 Anti-Inflammatory Biologics
5.2.2 Nonsteroidal anti inflammatory drugs (NSAIDS)
5.2.3 Corticosteroids
5.2.4 Immune-selective anti-inflammatory derivative (ImSAID)
5.2.5 Other Drug Classes
5.3 By Sales Channel
5.3.1 Prescription
5.3.2 Over the Counter (OTC)
5.4 Geography
5.4.1 North America United States Canada Mexico
5.4.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.4.3 Asia Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle East and Africa GCC South Africa Rest of Middle East and Africa
5.4.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 Pfizer Inc.
6.1.2 Amgen Inc.
6.1.3 GlaxoSmithKline PLC
6.1.4 Johnson & Johnson
6.1.5 Novartis AG
6.1.6 F. Hoffmann-La Roche AG
6.1.7 AbbVie Inc
6.1.8 AstraZeneca PLC
6.1.9 Merck & Company, Inc.
6.1.10 Eli Lily and Company

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Pfizer Inc.
  • Amgen Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Novartis AG
  • F. Hoffmann-La Roche AG
  • AbbVie Inc
  • AstraZeneca PLC
  • Merck & Company, Inc.
  • Eli Lily and Company